

MARINUS PHARMACEUTICALS, INC.

Science and Technology Committee Charter

1. Authority and Purpose

The Board of Directors (the “Board”) of Marinus Pharmaceuticals, Inc. (the “Company”) has established a Science and Technology Committee (the “Committee”) to assist the Board’s oversight of the Company’s research and development activities and to advise the Board with respect to strategic and tactical scientific issues. The Committee shall undertake those specific duties and responsibilities set forth below and such other duties as the Board shall from time to time prescribe.

2. Composition

The Committee members shall be appointed by the Board from among its members. The Committee will consist of such number of directors as the Board shall from time to time determine. Unless otherwise directed by the Board, each Committee member shall serve until such member ceases to serve as a member of the Board or until his or her successor has been appointed by the Board. A Committee member may be removed at any time by the Board. Committee members should understand scientific matters and have experience and/or expertise and an ability to contribute to the Committee’s areas of responsibility in science and technology, including but not limited to pharmaceutical research and development, clinical research, drug formulation, drug development experience, and/ or regulatory experience.

3. Structure and Meetings

The Committee shall conduct its business in accordance with this Charter, the Company’s By-laws and any direction by the Board.

In discharging its responsibilities, the Committee shall meet as often as it determines necessary or advisable, but not less frequently than once per year.

As necessary or desirable, the Chairperson may invite any director, officer or employee of the Company, or other persons whose advice and counsel are sought by the Committee, to be present at meetings of the Committee.

The Committee may form and delegate authority to one or more subcommittees (including a subcommittee consisting of a single member), as it deems appropriate from time to time under the circumstances.

The Committee shall regularly report to the full Board on the Committee’s proceedings and any actions taken by the Committee.

4. Authority and Responsibilities

General. The Science and Technology Committee shall discharge its responsibilities and shall assess the information provided by the Company's management, in accordance with its business judgment.

Science and Technology Matters. The Science and Technology Committee shall function as a knowledgeable and objective group of scientists and non-scientists to consider and report periodically to the Board on matters relating to the Company's research and development initiatives.

The Science and Technology Committee shall:

- review the overall scientific and research and development strategy of the Company;
- review the Company's research and development programs;
- review the Company's pipeline;
- review, evaluate and advise the board and management regarding the long-term strategic goals and objectives of the Company's research and development programs; and
- review cognate external scientific research, discoveries and commercial developments, as appropriate;

Additional Duties. The Science and Technology Committee shall have such other duties as may be delegated from time to time by the Board.

5. Performance Evaluation

The Committee shall review and assess the adequacy of this Charter from time to time, as it deems appropriate and recommend any proposed changes to the Board for approval. The Committee shall also perform an evaluation of its own performance.

6. Committee Resources

The Committee shall be empowered, without the approval of the Board or management, to engage, oversee the work of, and compensate such independent scientific and other advisors as it determines necessary to carry out its duties. The Committee shall receive appropriate funding, as determined by the Committee, from the Company for payment of (a) reasonable compensation to any advisor employed by the Committee; and (b) ordinary administrative expenses of the Committee that are necessary or appropriate in carrying out its duties. Such independent advisors may be the regular advisors to the Company.

Adopted on August 3, 2021